MarketPulse
A

$AGIO

6 articles found
5 positive
1 negative
0 neutral
The Motley FoolThe Motley Fool··Eric Volkman

Agios Pharmaceuticals Surges 13% on Beat Earnings, Expanding Mitapivat Market

Agios Pharmaceuticals surged 13% on strong Q1 earnings, with mitapivat revenue jumping 138% to $20.7M. Company plans supplemental FDA application for sickle cell disease expansion.
AGIOFDA approvalsickle cell disease
The Motley FoolThe Motley Fool··Lee Samaha

Novo Nordisk's Sickle Cell Win Decimates Agios Stock 23% in Single Day

Agios Pharmaceuticals plunged 23% after Novo Nordisk's superior sickle cell drug trial results overshadowed Agios' failed mitapavit candidate, threatening its commercial viability.
NVOAGIOFDA approvalclinical trial results
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Alpha Thalassemia Market Set for Robust Growth Through 2036 on Gene Therapy Advances

Alpha thalassemia market poised for significant expansion driven by rising prevalence, diagnostic advances, and pipeline therapies from $AGIOS and $NVO through 2036.
BMYCELGrNVOAGIOclinical trialsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Agios Pharmaceuticals Eyes Accelerated FDA Approval Path for Mitapivat in Sickle Cell

Agios Pharmaceuticals to report Q1 2026 results April 29 amid FDA accelerated approval pursuit for sickle cell mitapivat and UAE thalassemia approval.
AGIOrare diseasesFDA
The Motley FoolThe Motley Fool··James Brumley

Agios Pharma Soars 21% on FDA Fast-Track Win for Sickle Cell Drug

Agios Pharmaceuticals surges on FDA accelerated approval for mitapivat sickle cell treatment, enabling faster path to full approval despite company's ongoing losses.
AGIObiotechpharmaceutical
The Motley FoolThe Motley Fool··Andy Gould

Agios Insider Sells $82K in Stock, But RSU Vesting—Not Confidence—Tells Real Story

Agios insider Krishnan sells $82K in shares via routine RSU tax-withholding event. Retains 16,200 unvested RSUs and recent equity grants signal confidence amid PYRUKYND's 86% revenue growth.
XLVAGIOIHEFDA approvalbiotech
$AGIO Stock News & Sentiment | MarketPulse